Gut phageome in Mexican Americans: a population at high risk for metabolic dysfunction-associated steatotic liver

Suet-Ying Kwan1, Caroline M Sabotta1, Lorenzo R Cruz1

  • 1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Msystems
|August 21, 2024
PubMed

Insights

Gut phageome signatures are linked to metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes in Mexican Americans. Specific phage groups like Inoviridae, Escherichia, and Crassvirales show distinct associations with these conditions.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Genetics

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes disproportionately affect Mexican Americans.
  • The gut microbiome's role in MASLD is known, but the gut phageome's involvement remains understudied.
  • Phages significantly influence gut bacterial communities and host health.

Purpose of the Study:

  • To characterize the gut phageome in Mexican Americans with MASLD and/or diabetes.
  • To identify phage signatures associated with liver steatosis and diabetes.
  • To explore potential bacterial targets for phage therapy.

Main Methods:

  • Cross-sectional study of 340 Mexican American subjects in South Texas.
  • Stool shotgun metagenomic sequencing to analyze the gut phageome.
  • Transient elastography used for liver steatosis screening.

Main Results:

  • Inter-individual phageome variations correlated with gender, country of birth, diabetes, and liver steatosis.
  • Enrichment of Inoviridae phages was associated with both diabetes and liver steatosis.
  • Diabetes showed enrichment of temperate Escherichia phages, while liver steatosis was linked to depleted Lactococcus phages and enriched Crassvirales phages.

Conclusions:

  • Distinct gut phageome signatures are associated with diabetes and liver steatosis in Mexican Americans.
  • These phage signatures could aid in risk modeling and disease prevention strategies.
  • Identified phage-bacterial associations may inform future phage therapy development.